Current Report · Items 2.02, 9.01 · 8-K

aTyr Pharma, Inc.

ATYRNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Mar 5, 2026Accepted Mar 5, 2026, 11:03 AM ESTCIK 1339970Accession 0001339970-26-000006

Company context

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its

Current securities

ATYRNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) atyr-ex99_1.htm

EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO - March 5, 2026 - aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2025 results and provided a corporate update. “In 2025 we announced results from our Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD) wher…

Open exhibit ↗